

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robert Hugh BRADBURY <i>et al.</i>)	Confirmation No.: 3653
)	
Application No.: 10/578,663)	Group Art Unit: <i>Unassigned</i>
)	
Filed: May 9, 2006)	Examiner: <i>Unassigned</i>
)	
For: QUINAZOLINE DERIVATIVES)	Date: January 17, 2007

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Citation of Technically Related U.S. Patent Applications

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Hennequin et al.	11/443,395 May 31, 2006		WO 03/040109 May 15, 2003
Hennequin et al.	11/443,208 May 31, 2006		WO 03/040108 May 15, 2003
Bradbury et al.	10/554,202 October 24, 2005		WO 2004/093880 November 4, 2004
Bradbury et al.	10/571,851 March 15, 2006		WO 2005/026151 March 24, 2005
Bradbury et al.	10/572,262 March 16, 2006		WO 2005/026152 March 24, 2005
Bradbury et al.	10/857,342 June 1, 2004		WO 2005/012290 November 4, 2004
Bradbury et al.	11/628,011 November 30, 2006		WO 2005/118572 December 15, 2005

With the exception of the documents listed in the table above in bold (for which a copy was provided with the previously filed Information Disclosure Statement), a copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith. Consideration of each listed application is earnestly solicited

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

A handwritten signature in black ink, appearing to read 'Donald J. Bird', is written over a horizontal line.

Date: January 17, 2007
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

